Aaron Mitchell
@thewonkologist.bsky.social
Medical oncologist and health services researcher. Focusing on health care costs, physician-industry COI, and oncology reimbursement reform. Opinions mine.
Reposted by Aaron Mitchell
@medscape.com piece on biosimilars policy, including our recent @jamanetworkopen.com study on biosimilar prices:
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
FDA Aims to Streamline Biosimilar Drug Development
FDA proposals include ‘major updates’ to simplify biosimilarity studies, reduce unnecessary clinical testing, and ease the process for making biosimilars interchangeable with brand-name biologics.
www.medscape.com
November 21, 2025 at 5:23 PM
@medscape.com piece on biosimilars policy, including our recent @jamanetworkopen.com study on biosimilar prices:
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
In good company alongside some cutting-edge basic science, our recent @bmj.com study examining the association between cancer drug profitability and utilization made the @mskcancercenter.bsky.social research highlights!
www.mskcc.org/news/msk-res...
@dusetzinas.bsky.social
www.mskcc.org/news/msk-res...
@dusetzinas.bsky.social
MSK Research Highlights, November 20, 2025
New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new syst...
www.mskcc.org
November 20, 2025 at 9:00 PM
In good company alongside some cutting-edge basic science, our recent @bmj.com study examining the association between cancer drug profitability and utilization made the @mskcancercenter.bsky.social research highlights!
www.mskcc.org/news/msk-res...
@dusetzinas.bsky.social
www.mskcc.org/news/msk-res...
@dusetzinas.bsky.social
It had been far too long since my last GREETINGS OF THE DAY email! This one may be my new all time favorite.
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
November 14, 2025 at 6:50 PM
It had been far too long since my last GREETINGS OF THE DAY email! This one may be my new all time favorite.
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
How much better could you signal "this is spam"? LOL right now 🤣
@ankurfactorial.bsky.social
When someone leaves the “-ized” out of “generalized estimating equations”
And now you too can shame other people that don't know this! 😜
November 14, 2025 at 1:59 PM
When someone leaves the “-ized” out of “generalized estimating equations”
Reposted by Aaron Mitchell
NEW: We’ve uncovered the first known example of taxpayer money flowing from DHS to businesses controlled by Kristi Noem’s allies and friends.
It’s part of a money trail that’s been shrouded in secrecy—and involves $220 million, a mysterious Delaware LLC & a horse named Gill.
It’s part of a money trail that’s been shrouded in secrecy—and involves $220 million, a mysterious Delaware LLC & a horse named Gill.
November 14, 2025 at 12:20 PM
NEW: We’ve uncovered the first known example of taxpayer money flowing from DHS to businesses controlled by Kristi Noem’s allies and friends.
It’s part of a money trail that’s been shrouded in secrecy—and involves $220 million, a mysterious Delaware LLC & a horse named Gill.
It’s part of a money trail that’s been shrouded in secrecy—and involves $220 million, a mysterious Delaware LLC & a horse named Gill.
KIDS.
Every morning, how does it always take 20 minutes between “ready to leave” and “ready to leave”????
Every morning, how does it always take 20 minutes between “ready to leave” and “ready to leave”????
November 14, 2025 at 1:48 PM
KIDS.
Every morning, how does it always take 20 minutes between “ready to leave” and “ready to leave”????
Every morning, how does it always take 20 minutes between “ready to leave” and “ready to leave”????
Reposted by Aaron Mitchell
“Housing shortage – Jews to blame," letter sticker, German Reich, 1938
zwangsraeume.berlin/en/context
zwangsraeume.berlin/en/context
November 14, 2025 at 2:16 AM
“Housing shortage – Jews to blame," letter sticker, German Reich, 1938
zwangsraeume.berlin/en/context
zwangsraeume.berlin/en/context
Reposted by Aaron Mitchell
NIH program officer @jenna-m-norton.bsky.social has been placed on admin leave, sources say.
Norton has been outspoken about the Trump administration's dismantling of science, and she signed the Bethesda Declaration.
Bhattacharya has said that "science is dead without free speech".
Norton has been outspoken about the Trump administration's dismantling of science, and she signed the Bethesda Declaration.
Bhattacharya has said that "science is dead without free speech".
November 13, 2025 at 10:04 PM
NIH program officer @jenna-m-norton.bsky.social has been placed on admin leave, sources say.
Norton has been outspoken about the Trump administration's dismantling of science, and she signed the Bethesda Declaration.
Bhattacharya has said that "science is dead without free speech".
Norton has been outspoken about the Trump administration's dismantling of science, and she signed the Bethesda Declaration.
Bhattacharya has said that "science is dead without free speech".
Honored to have been a co-author on you first thread in this role! But the credit is really all to Dr. Paul, who led this study.
I was honored to have been asked to collaborate by the @portalresearch.org team
I was honored to have been asked to collaborate by the @portalresearch.org team
Starting with this article on ICI pricing from @thewonkologist.bsky.social and colleagues!
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
Do more approved drugs with the same mechanism reduce prices?
ascopubs.org/doi/10.1200/...
November 12, 2025 at 4:33 AM
Honored to have been a co-author on you first thread in this role! But the credit is really all to Dr. Paul, who led this study.
I was honored to have been asked to collaborate by the @portalresearch.org team
I was honored to have been asked to collaborate by the @portalresearch.org team
Reposted by Aaron Mitchell
Excited to see this study out in the world! Looks at the counterfactual of a world in which biosimilars didn't launch. Always fun working with @thewonkologist.bsky.social
Our new study is out today in @jamanetworkopen.com!
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market
This cohort study evaluates the associations of biosimilar entry to the market with the prices of originator biologics under Medicare Part B reimbursement.
jamanetwork.com
November 11, 2025 at 7:37 PM
Excited to see this study out in the world! Looks at the counterfactual of a world in which biosimilars didn't launch. Always fun working with @thewonkologist.bsky.social
Our new study is out today in @jamanetworkopen.com!
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market
This cohort study evaluates the associations of biosimilar entry to the market with the prices of originator biologics under Medicare Part B reimbursement.
jamanetwork.com
November 11, 2025 at 5:39 PM
Our new study is out today in @jamanetworkopen.com!
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
We looked at trends in biologic drug prices after biosimilar competition.
Key takeaways: savings from biosimilars are substantial, but take longer to accrue than commonly seen with generic small molecules.
1/
jamanetwork.com/journals/jam...
Reposted by Aaron Mitchell
As the ~discourse~ seems to bend interminably towards Republicans trying to figure out how they can (further) HDHP-ify ACA coverage, it's worth revisiting what is probably our best (most rigorous) study on the effect of deductibles in health insurance.
academic.oup.com/qje/article-...
academic.oup.com/qje/article-...
November 10, 2025 at 9:51 PM
As the ~discourse~ seems to bend interminably towards Republicans trying to figure out how they can (further) HDHP-ify ACA coverage, it's worth revisiting what is probably our best (most rigorous) study on the effect of deductibles in health insurance.
academic.oup.com/qje/article-...
academic.oup.com/qje/article-...
Postdoc opportunity at @mskcancercenter.bsky.social ! Read about and apply to OPTICS below:
November 8, 2025 at 4:15 PM
Postdoc opportunity at @mskcancercenter.bsky.social ! Read about and apply to OPTICS below:
Reposted by Aaron Mitchell
Cool. What would you call the other wing then? www.nytimes.com/2025/11/03/u...
November 6, 2025 at 12:38 PM
Cool. What would you call the other wing then? www.nytimes.com/2025/11/03/u...
This study could be titled "what makes doctors quit"
The answers are saddening:
1) being a woman
2) practicing in a rural area
3) caring for sicker patients and dual-eligible patients
www.acpjournals.org/doi/10.7326/...
The answers are saddening:
1) being a woman
2) practicing in a rural area
3) caring for sicker patients and dual-eligible patients
www.acpjournals.org/doi/10.7326/...
Trends in and Predictors of Physician Attrition From Clinical Practice Across Specialties: A Nationwide, Longitudinal Analysis: Annals of Internal Medicine: Vol 0, No 0
Background: The United States faces a predicted shortage of 36 500 physicians by 2036, with an increasing proportion of physicians leaving clinical practice or expressing an intent to do so. Evidence ...
www.acpjournals.org
November 6, 2025 at 3:20 PM
This study could be titled "what makes doctors quit"
The answers are saddening:
1) being a woman
2) practicing in a rural area
3) caring for sicker patients and dual-eligible patients
www.acpjournals.org/doi/10.7326/...
The answers are saddening:
1) being a woman
2) practicing in a rural area
3) caring for sicker patients and dual-eligible patients
www.acpjournals.org/doi/10.7326/...
Our new study, out yesterday in @bmj.com !
👇🏼👇🏼👇🏼
👇🏼👇🏼👇🏼
New @bmj.com research estimates the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists
www.bmj.com/content/391/...
www.bmj.com/content/391/...
November 6, 2025 at 11:56 AM
Our new study, out yesterday in @bmj.com !
👇🏼👇🏼👇🏼
👇🏼👇🏼👇🏼
Our new study is published today in @bmj.com!
We studied whether oncologists tend to use cancer treatments that are more beneficial, more profitable, or both.
I was surprised by the results: clinical benefit mattered, profit did not.
1/
cc: @dusetzinas.bsky.social
www.bmj.com/content/391/...
We studied whether oncologists tend to use cancer treatments that are more beneficial, more profitable, or both.
I was surprised by the results: clinical benefit mattered, profit did not.
1/
cc: @dusetzinas.bsky.social
www.bmj.com/content/391/...
Provider billing margin and cancer treatment selection: population based cohort study
Objective To estimate the association between the billing (profit) margin and clinical benefit of cancer treatments and use by oncologists.
Design Retrospective population based cohort study
Setting...
www.bmj.com
November 5, 2025 at 5:33 PM
Our new study is published today in @bmj.com!
We studied whether oncologists tend to use cancer treatments that are more beneficial, more profitable, or both.
I was surprised by the results: clinical benefit mattered, profit did not.
1/
cc: @dusetzinas.bsky.social
www.bmj.com/content/391/...
We studied whether oncologists tend to use cancer treatments that are more beneficial, more profitable, or both.
I was surprised by the results: clinical benefit mattered, profit did not.
1/
cc: @dusetzinas.bsky.social
www.bmj.com/content/391/...
3 year old: “I want to be a firefighter and not a doctor because I want to save people”
Ouch
Ouch
November 5, 2025 at 3:13 AM
3 year old: “I want to be a firefighter and not a doctor because I want to save people”
Ouch
Ouch
Reposted by Aaron Mitchell
Important new analysis from @matthewherper.bsky.social and @lizzylawrence.bsky.social about the ongoing situation at FDA. This quote from an agency staffer sums up the potential concerns. www.statnews.com/2025/11/04/f...
November 4, 2025 at 2:41 PM
Important new analysis from @matthewherper.bsky.social and @lizzylawrence.bsky.social about the ongoing situation at FDA. This quote from an agency staffer sums up the potential concerns. www.statnews.com/2025/11/04/f...
These quoted phrases are precisely what we knew an agency with Vinay Prasad in leadership would look like.
Experts worry FDA’s credibility is being shredded by scandal and 'embarassing' ‘soap opera’ 'clown show' www.statnews.com/2025/11/04/f...
Experts worry FDA’s credibility is being shredded by scandal and 'soap opera'
Experts worry that the FDA’s credibility is being shredded by scandal and "soap opera."
www.statnews.com
November 4, 2025 at 3:26 PM
These quoted phrases are precisely what we knew an agency with Vinay Prasad in leadership would look like.
Reposted by Aaron Mitchell
💊 Prescription drug prices have long risen faster than inflation, straining budgets for patients and the government alike.
A new Medicare policy aims to slow that trend, and it could save billions over the next decade.
Explore the details in our new explainer:
A new Medicare policy aims to slow that trend, and it could save billions over the next decade.
Explore the details in our new explainer:
How Inflation Rebates Can Curb Drug Price Increases
To discourage price hikes on brand-name drugs, the IRA requires manufacturers to pay inflation rebates to Medicare if prices increase faster than inflation.
bit.ly
November 4, 2025 at 1:58 PM
💊 Prescription drug prices have long risen faster than inflation, straining budgets for patients and the government alike.
A new Medicare policy aims to slow that trend, and it could save billions over the next decade.
Explore the details in our new explainer:
A new Medicare policy aims to slow that trend, and it could save billions over the next decade.
Explore the details in our new explainer:
Reposted by Aaron Mitchell
Love to see an implementation win in @ascocancer.bsky.social/ #JCOOP ⬇️
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
November 4, 2025 at 3:52 AM
Love to see an implementation win in @ascocancer.bsky.social/ #JCOOP ⬇️
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
Our new study is out today in JCO Oncology Practice @ascocancer.bsky.social!
We studied the use of guideline-concordant bone agents for prostate cancer, and found a large degree of inter-provider variation...
1/
ascopubs.org/doi/10.1200/...
We studied the use of guideline-concordant bone agents for prostate cancer, and found a large degree of inter-provider variation...
1/
ascopubs.org/doi/10.1200/...
Interprovider Variation in Initiation of Bone-Modifying Agents for Patients With Prostate Cancer | JCO Oncology Practice
PURPOSEOncology clinical practice guidelines recommend bone-modifying agents (BMAs) to decrease
skeletal-related events for patients with metastatic castration-resistant prostate
cancer (mCRPC) and ag...
ascopubs.org
November 4, 2025 at 3:39 AM
Our new study is out today in JCO Oncology Practice @ascocancer.bsky.social!
We studied the use of guideline-concordant bone agents for prostate cancer, and found a large degree of inter-provider variation...
1/
ascopubs.org/doi/10.1200/...
We studied the use of guideline-concordant bone agents for prostate cancer, and found a large degree of inter-provider variation...
1/
ascopubs.org/doi/10.1200/...
"None of the proposals outlined by Makary and Prasad justify firing hundreds of scientific experts dedicated to protecting public health. Staffing and budget cuts will only further diminish the FDA’s capacity to approve drugs in a timely manner."
jamanetwork.com/journals/jam...
True words
jamanetwork.com/journals/jam...
True words
Priorities of the US Food and Drug Administration
To the Editor As the chair of the Doctors for America Food and Drug Administration (FDA) Task Force, I am responding to the recent Viewpoint “Priorities for a New FDA” by FDA Commissioner Martin A. Ma...
jamanetwork.com
November 3, 2025 at 11:31 PM
"None of the proposals outlined by Makary and Prasad justify firing hundreds of scientific experts dedicated to protecting public health. Staffing and budget cuts will only further diminish the FDA’s capacity to approve drugs in a timely manner."
jamanetwork.com/journals/jam...
True words
jamanetwork.com/journals/jam...
True words